Omnilux™ was originally developed at the Paterson Institute for Cancer Research. Its optimized intensity and adjustable dose function have been used in the treatment of thousands of non-melanoma lesions. It is especially effective in cosmetically sensitive areas and for lesions in poor healing sites. Compared with conventional modalities, treatment outcomes are excellent, with significantly fewer adverse events.
Specifically, the use of Omnilux along with ALA-PDT has been shown to be optimally effective in treating:
- Non-hyperkeratotic actinic keratoses (AKs) on the face, chest, and scalp.
- Bowen’s disease
- Superficial Basal cell carcinomas (sBCCs) (less than 2 mm thick).